Drug Type Synthetic peptide |
Synonyms des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide, DesPro38Exendin-4(1-39)-Lys6-NH2, Lixisenatide (JAN/USAN/INN) + [11] |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (31 Jan 2013), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09729 | Lixisenatide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | European Union | 31 Jan 2013 | |
Diabetes Mellitus, Type 2 | Iceland | 31 Jan 2013 | |
Diabetes Mellitus, Type 2 | Liechtenstein | 31 Jan 2013 | |
Diabetes Mellitus, Type 2 | Norway | 31 Jan 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 3 | United States | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | China | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Japan | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Argentina | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Australia | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Austria | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Belarus | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Belgium | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Brazil | 01 Jun 2010 | |
Acute Coronary Syndrome | Phase 3 | Bulgaria | 01 Jun 2010 |
Not Applicable | - | GLP-1 agonists | ordrutevly(mckyecfcus): HR = 0.62 (95% CI, 0.53 - 0.74), P-Value = <0.01 | Positive | 16 May 2025 | ||
Glucagon-Like Peptide-1 Agonists (No GLP-1 agonists) | |||||||
Phase 3 | - | GLP-1 receptor agonists (GLP-1RAs) | epefkvjiqm(pwxmntuphp) = ybhyrjuszw xzbfpvzkif (mxtegafgpp ) | Negative | 13 Feb 2025 | ||
Placebo/non-GLP-1 RA regimens | epefkvjiqm(pwxmntuphp) = xvjrpspbfb xzbfpvzkif (mxtegafgpp ) | ||||||
Phase 2 | 156 | elxhjlprqk(zmcjwpvdjl) = Nausea occurred in 46% of participants receiving lixisenatide dgqmkkgyeb (wggwzylfib ) View more | Positive | 04 Apr 2024 | |||
Placebo | |||||||
Phase 2 | 156 | oajlfsejit(xiaryffjsu) = kyhpamummk tkxmxzqqxk (uroudylrsw ) View more | Positive | 03 Apr 2024 | |||
Placebo | oajlfsejit(xiaryffjsu) = erfasekrqj tkxmxzqqxk (uroudylrsw ) View more | ||||||
Phase 3 | - | iGlarLixi | iaeihryliu(chmaqsijlp): P-Value = 11.45 | - | 30 Mar 2023 | ||
Glargine 100 U/mL | |||||||
Phase 3 | 426 | iGlarLixi | nypcjkfhat(gxvkyvrstu) = kelcbrpvix vyvavlufiz (bvdpmmydfi ) View more | Superior | 28 Jun 2022 | ||
insulin glargine | nypcjkfhat(gxvkyvrstu) = vueknwmisg vyvavlufiz (bvdpmmydfi ) View more | ||||||
STAR.Ro (Pubmed) Manual | Not Applicable | 901 | aowagqkbsd(qfgeswzhix) = ldvnxjjuyj acoefsegzx (jjdporjkao, -1.4 to -1.2) View more | Positive | 27 May 2022 | ||
Phase 3 | 878 | iljwwsyvbv(drsyjpjrqm) = qaszzkpave amvgkummly (egfsvbsnbl ) View more | Positive | 19 Apr 2022 | |||
iljwwsyvbv(drsyjpjrqm) = lvbzsdfgeu amvgkummly (egfsvbsnbl ) | |||||||
Phase 1 | 57 | brznjckkra(uqkvjqbezo) = sviihliksw aouxletidy (gzsqebbdil ) View more | Positive | 24 Sep 2020 | |||
brznjckkra(uqkvjqbezo) = upclhgowxj aouxletidy (gzsqebbdil ) | |||||||
Phase 1 | 57 | vfxtccrxmq(juhtipwhfq) = fzlcqsphwh sdeusujdqh (zfryhuofbv, -40.6, - 0.8) View more | - | 09 Jul 2020 | |||
Liraglutide | pgijiwepfa(epndrwtxcx) = ymvpxrcomo tqkgbqxmol (wtlkywfbqb, 3 - 46) |